Bifunctional TGF-beta Antagonist/IL-15 Protein Complex HCW9218 clinical trials
Also written HCW9218.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses Bifunctional TGF-beta Antagonist/IL-15 Protein Complex HCW9218 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HCW9218
- 3
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
ImmunityBio, Inc. (1) · Masonic Cancer Center, University of Minnesota (1) · Haider Mahdi (1)
Studies
Open first, then newest update. How each study uses Bifunctional TGF-beta Antagonist/IL-15 Protein Complex HCW9218 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- HCW9218 for Advanced Pancreatic CancerCompletedPhase 1/2ImmunityBio, Inc.NCT05304936Written as HCW9218How we know
- HCW9218 in Select Advanced Solid TumorsCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT05322408Written as HCW9218How we know
- Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian CancerWithdrawnPhase 2Haider MahdiNCT05145569Written as HCW9218How we know